• Proven efficacy with 20 years of clinical experience1
  • The first extended-release (ER) opioid with FDA-approved labeling describing abuse-deterrent characteristics and claims2
    • However, abuse of OxyContin by injection and intranasal routes, as well as by the oral route, is still possible
  • Broad formulary coverage* with preferred branded tier status may enable patients to obtain OxyContin at the lowest available branded co-pay
    • Inclusion on formulary does not imply superior clinical efficacy or safety

*Covered represents on formulary (on any tier, with or without restrictions) and may include quantity limits, prior authorizations and/or step edit restrictions.

Source: Managed Markets Insight & Technology, LLC, database as of June 2016. Please note that formularies are subject to change. Please check with the health plan directly to confirm coverage for individual patients. Patient costs may vary among plans.

References: 1. Data on file. Purdue Pharma L.P. 2. U.S. Department of Health and Human Services. FDA Supplemental Approval Letter. April 2013. h‌ttp://w‌ww.acce‌ssdata.fd‌a.go‌v/drug‌satfda_do‌cs/appl‌etter/201‌3/02‌2272Orig1s‌014Ltr.p‌df. Accessed May 25, 2016.